Remus Pharmaceuticals Limited (NSE:REMUS)

Market Cap	7.90B -36.7%
Revenue (ttm)	7.48B +63.8%
Net Income	335.10M +12.1%
EPS	27.37 +7.9%
Shares Out	11.66M
PE Ratio	24.76
Forward PE	n/a
Dividend	1.00 (0.14%)
Ex-Dividend Date	Nov 14, 2025

Volume	3,500
Average Volume	2,670
Open	690.00
Previous Close	700.00
Day's Range	671.00 - 690.00
52-Week Range	611.05 - 1,145.00
Beta	0.01
RSI	48.16
Earnings Date	Feb 9, 2026

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels,...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2015
• Employees: 68
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: REMUS

Financial Performance

In fiscal year 2025, Remus Pharmaceuticals's revenue was 6.20 billion, an increase of 191.33% compared to the previous year's 2.13 billion. Earnings were 290.70 million, an increase of 41.67%.